Edwin Mateo Quispe Bellido, Medical Oncologist at Next Oncology – Hospital Quirónsalud de Madrid SL, shared a post on LinkedIn:
“Our work on B7-H4 and CCR8⁺ Tregs in the tumor microenvironment has now been published in Cancer Immunology Research (AACR).
I am pleased to share that our abstract has been published in Cancer Immunology Research, the official journal of the American Association for Cancer Research (AACR): AACR Journals
“B7-H4 expression and CCR8⁺ Treg…”
Available here.
What we studied
In this study, we analyzed:
- The tumor expression of B7-H4, an emerging checkpoint with growing clinical development.
- The presence of CCR8⁺ Tregs, an immunosuppressive subpopulation enriched in the tumor microenvironment.
- Their possible convergence as a functional immunosuppressive axis.
Our data give rise to a rational hypothesis:
- Anti-B7-H4 ADC → eliminates the tumor cell.
- CCR8 inhibitor → dismantles the intratumoral Treg niche.
- Result: cytotoxicity + structural immune release.
Perhaps the next frontier in immunotherapy is not to add more molecules, but to orchestrate them with mechanistic intent from early design.
I would like to give special thanks to Ilaria Colombo of IOSI, and the NEXT Oncology, an Avacare business Valentina Boni, Jesús Fuentes Antrás, and Juan Pablo Fusco collaborators and allies in our work to find treatment pathways for our patients.”
Title: Abstract A047: B7-H4 expression and CCR8+ Treg infiltration delineate an immune-cold molecular phenotype in ovarian cancer
Authors: Edwin MQ. Bellido, Valentina Boni, Jesus Fuentes, Juan Fusco, Ilaria Colombo
Read the Full Article.
